Iovance Biotherapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · San Carlos, CA
IOVA chart
What traders are saying about $IOVA
Latest postsIovance Biotherapeutics, Inc. news
- Best Momentum Stocks to Buy for October 27th
Yahoo Finance ·
- Is Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?
Yahoo Finance ·
- Iovance Biotherapeutics (IOVA) Stock Looks Pricey As Fresh Lifileucel Data Lands
Simply Wall Street ·
- Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
Yahoo Finance ·
- A live webcast at 8:30 a.m. Eastern will cover Iovance's third-quarter results and updates.
Stock Titan ·
- New Strong Buy Stocks for October 27th
Yahoo Finance ·
- Iovance Biotherapeutics Inc. Research & Ratings | IOVA
Barron's ·
- Iovance Biotherapeutics, Inc. (IOVA) Stock Price, News, Quote & History
Yahoo! Finance Canada ·
- H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $20
Moomoo ·
- Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
Yahoo Finance ·
- Weekly Recap: Iovance Phase 2 melanoma ORR 62.5% and $304M cash runway
TradingView ·
- A one-time cancer treatment shrank tumors in 4 of 8 patients with rare sarcomas.
Stock Titan ·
Iovance Biotherapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $263.5M | $164.1M | $1.2M | – |
| Net income | -$391.0M | -$372.2M | -$444.0M | -$395.9M |
| Diluted EPS | $-1.09 | $-1.28 | $-1.89 | $-2.49 |
| Total assets (year end) | $913.2M | $910.4M | $780.4M | $664.0M |
| Cash and equivalents (year end) | $163.1M | $115.7M | $114.9M | $231.7M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Iovance Biotherapeutics, Inc.
- Ticker
- IOVA (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- San Carlos, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1425205
- Former names
- Lion Biotechnologies, Inc., Genesis Biopharma, Inc, FREIGHT MANAGEMENT CORP
Frequently asked questions
What exchange is Iovance Biotherapeutics, Inc. listed on?
Iovance Biotherapeutics, Inc. trades on the Nasdaq under the ticker symbol IOVA.
What industry is Iovance Biotherapeutics, Inc. in?
Iovance Biotherapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Iovance Biotherapeutics, Inc. headquartered?
Iovance Biotherapeutics, Inc.'s business address on file with the SEC is in San Carlos, CA.
When does Iovance Biotherapeutics, Inc.'s fiscal year end?
Iovance Biotherapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Iovance Biotherapeutics, Inc. report?
Iovance Biotherapeutics, Inc. reported $263.5M in revenue for calendar year 2025, according to its SEC filings.